1. Inicio
  2. Proyectos y Estudios
  3. Estudio en fase Ib/II de escalado y expansión de dosis, abierto y multicéntrico para evaluar la seguridad, tolerabilidad, farmacocinética, farmacodinamia y actividad antitumoral de PF-07220060 en combinación con PF-07104091 más Endocrinoterapia en participantes con tumores sólidos avanzados.

Estudio en fase Ib/II de escalado y expansión de dosis, abierto y multicéntrico para evaluar la seguridad, tolerabilidad, farmacocinética, farmacodinamia y actividad antitumoral de PF-07220060 en combinación con PF-07104091 más Endocrinoterapia en participantes con tumores sólidos avanzados.

Datos básicos

Protocolo:
C4891001
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Año de incio:
2024
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

PFIZER INC.

Resultados del Ensayo Clínico

[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.

Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin

Article. 10.1016/j.farma.2024.08.002. 2024

  • Open Access.

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


A Gadolinium(III) Complex Based on Pyridoxine Molecule with Single-Ion Magnet and Magnetic Resonance Imaging Properties.

Orts-Arroyo, Marta; (...); Martinez-Lillo, Jose

Article. 10.3390/ijms25042112. 2024

  • Open Access.

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Gonzalez-Martin, Antonio; (...); Selle, Frederic

Article. 10.1200/JCO.24.00668. 2024


Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.

Pérez-Alenda S; (...); Núñez-Cortés R

Article. 10.1111/hae.14988. 2024

  • Open Access.

Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.

Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J

Article. 10.1007/s12094-024-03411-w. 2024

  • Open Access.

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.

Pena-Enriquez, Regina; (...); de la Haba-Rodriguez, Juan

Article. 10.1038/s41523-025-00718-x. 2025


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

  • Open Access.

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).

García-Donas J; (...); Navarro P

Article. 10.1016/j.ygyno.2024.10.019. 2024


Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial

Gustavo, Federico; (...); Albanell, Joan

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1029. 2024

  • Open Access.

Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial

Perez-Fidalgo, Jose Alejandro; (...); Gonzalez-Martin, Antonio

Meeting Abstract. 2024


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial

Albanell, Joan; (...); Rojo Todo, Federico Gustavo

Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1028. 2024

  • Open Access.

Campos de Estudio

Compartir